Literature DB >> 29188475

Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Marianne Lerch1, Carlo Mainetti2, Benedetta Terziroli Beretta-Piccoli3, Thomas Harr4.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered a delayed-type hypersensitivity reaction to drugs. They represent true medical emergencies and an early recognition and appropriate management is decisive for the survival. SJS/TEN manifest with an "influenza-like" prodromal phase (malaise, fever), followed by painful cutaneous and mucous membrane (ocular, oral, and genital) lesions, and other systemic symptoms. The difference between SJS, SJS/TEN overlap, and TEN is defined by the degree of skin detachment: SJS is defined as skin involvement of < 10%, TEN is defined as skin involvement of > 30%, and SJS/TEN overlap as 10-30% skin involvement. The diagnosis of different degrees of epidermal necrolysis is based on the clinical assessment in conjunction with the corresponding histopathology. The mortality rates for SJS and TEN have decreased in the last decades. Today, the severity-of-illness score for toxic epidermal necrolysis (SCORTEN) is available for SJS/TEN severity assessment. Drugs with a high risk of causing SJS/TEN are anti-infective sulfonamides, anti-epileptic drugs, non-steroidal anti-inflammatory drugs of the oxicam type, allopurinol, nevirapine, and chlormezanone. Besides conventional drugs, herbal remedies and new biologicals should be considered as causative agents. The increased risk of hypersensitivity reactions to certain drugs may be linked to specific HLA antigens. Our understanding of the pathogenesis of SJS/TEN has improved: drug-specific T cell-mediated cytotoxicity, genetic linkage with HLA- and non-HLA-genes, TCR restriction, and cytotoxicity mechanisms were clarified. However, many factors contributing to epidermal necrolysis still have to be identified, especially in virus-induced and autoimmune forms of epidermal necrolysis not related to drugs. In SJS/TEN, the most common complications are ocular, cutaneous, or renal. Nasopharyngeal, esophageal, and genital mucosal involvement with blisters, erosions as well as secondary development of strictures also play a role. However, in the acute phase, septicemia is a leading cause of morbidity and fatality. Pulmonary and hepatic involvement is frequent. The acute management of SJS/TEN requires a multidisciplinary approach. Immediate withdrawal of potentially causative drugs is mandatory. Prompt referral to an appropriate medical center for specific supportive treatment is of utmost importance. The most frequently used treatments for SJS/TEN are systemic corticosteroids, immunoglobulins, and cyclosporine A.

Entities:  

Keywords:  Drug reaction; Erythema multiforme; Intravenous immunoglobulins; Stevens-Johnson syndrome; Toxic epidermal necrolysis

Mesh:

Substances:

Year:  2018        PMID: 29188475     DOI: 10.1007/s12016-017-8654-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   10.817


  255 in total

1.  The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre.

Authors:  H Y Lee; Y L Lim; T Thirumoorthy; S M Pang
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

2.  Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.

Authors:  Karina L Vivar; Maria Deschaine; Jane Messina; Jennifer M Divine; Alejandro Rabionet; Nishit Patel; Michael A Harrington; Lucia Seminario-Vidal
Journal:  J Cutan Pathol       Date:  2017-01-23       Impact factor: 1.587

3.  Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.

Authors:  Tai-Ming Ko; Wen-Hung Chung; Chun-Yu Wei; Han-Yu Shih; Jung-Kuei Chen; Chia-Hsien Lin; Yuan-Tsong Chen; Shuen-Iu Hung
Journal:  J Allergy Clin Immunol       Date:  2011-09-14       Impact factor: 10.793

4.  Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.

Authors:  Yung-Tsu Cho; Jheng-Wei Lin; Yi-Chun Chen; Chia-Ying Chang; Cheng-Hsiang Hsiao; Wen-Hung Chung; Chia-Yu Chu
Journal:  J Am Acad Dermatol       Date:  2014-01-02       Impact factor: 11.527

5.  Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?

Authors:  Rochelle Mandelcorn; Neil H Shear
Journal:  J Am Acad Dermatol       Date:  2003-04       Impact factor: 11.527

6.  CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Esther Morel; Salvador Escamochero; Rosario Cabañas; Rosa Díaz; Ana Fiandor; Teresa Bellón
Journal:  J Allergy Clin Immunol       Date:  2010-02-04       Impact factor: 10.793

7.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.

Authors:  Christa Prins; Francisco A Kerdel; R Steven Padilla; Thomas Hunziker; Sergio Chimenti; Isabelle Viard; Davide N Mauri; Kirsten Flynn; Jennifer Trent; David J Margolis; Jean-Hilaire Saurat; Lars E French
Journal:  Arch Dermatol       Date:  2003-01

8.  A study of HLA-B∗15:02 in a Sri Lankan population: Implications for pharmacogenomic testing.

Authors:  K M D Gunathilake; K T Wettasinghe; V H W Dissanayake
Journal:  Hum Immunol       Date:  2016-04-06       Impact factor: 2.850

9.  Mortality and use of the auxiliary score in extensive toxic epidermal necrolysis patients admitted to an adult burns referral centre.

Authors:  Patrick D Mahar; Jason Wasiak; Heather Cleland; David Watters; Eldho Paul; Philip Marsh; Douglas Gin
Journal:  Dermatology       Date:  2013-09-27       Impact factor: 5.366

10.  Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.

Authors:  Lauren Knight; Gail Todd; Rudzani Muloiwa; Mushi Matjila; Rannakoe J Lehloenya
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

View more
  50 in total

1.  Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.

Authors:  Ratchaya Lertnawapan; Kanon Jatuworapruk
Journal:  Clin Rheumatol       Date:  2020-06-30       Impact factor: 2.980

2.  Stevens-Johnson syndrome.

Authors:  Satvinder Singh Bakshi
Journal:  Intern Emerg Med       Date:  2018-11-08       Impact factor: 3.397

3.  A Young Man with Red Eyes, Polymorphous Rash, and Mucositis-an On-the-Spot Diagnosis.

Authors:  Aldo Barajas-Ochoa; Nora Montealegre; Arturo Perez-Peralta
Journal:  J Gen Intern Med       Date:  2020-01-21       Impact factor: 5.128

4.  An atypical presentation of toxic epidermal necrolysis without mucosal involvement.

Authors:  Vikas Pathania; Sukriti Baveja; Anwita Sinha; J K Bhatia
Journal:  Med J Armed Forces India       Date:  2019-12-16

5.  Effectiveness and Safety of Early Short-Course, Moderate- to High-Dose Glucocorticoids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Retrospective Study.

Authors:  Zhenzhen Ye; Chunting Li; Hua Zhang; Chunlei Zhang; Xueyan Lu
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-19

6.  Toxic epidermal necrolysis caused by etonogestrel implantation: A rare presentation.

Authors:  Minorvi Amin; Christopher D Liao; Roger L Simpson
Journal:  JAAD Case Rep       Date:  2022-06-13

7.  Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis.

Authors:  Jerzy Strużyna; Agnieszka Surowiecka; Tomasz Korzeniowski; Patrycja Korulczyk; Lukasz Drozd; Aldona Stachura; Kamil Torres; Andrzej Krajewski
Journal:  BMC Med Inform Decis Mak       Date:  2022-10-19       Impact factor: 3.298

8.  Do topical ocular antihypertensives affect Dacryocystorhinostomy outcomes: The Coventry experience.

Authors:  Priyanka Mandal; Harpreet Ahluwalia
Journal:  Eye (Lond)       Date:  2021-02-26       Impact factor: 3.775

9.  Understanding Immune Responses to Surgical Transplant Procedures in Stevens Johnsons Syndrome Patients.

Authors:  Matias Soifer; Hazem M Mousa; Robert B Levy; Victor L Perez
Journal:  Front Med (Lausanne)       Date:  2021-05-21

Review 10.  Current Perspectives on Severe Drug Eruption.

Authors:  Jingzhan Zhang; Zixian Lei; Chen Xu; Juan Zhao; Xiaojing Kang
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-17       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.